Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumours

Official Title

Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumours

Summary:

Prospective study to obtain fresh tumour biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumours (NETs) or well-differentiated pancreatic neuroendocrine tumours (PanNETs) for molecular profiling.

Trial Description

Primary Outcome:

  • To prospectively collect tumour tissue and blood sample from patients with carcinoid tumours and islet cell tumours.
Secondary Outcome:
  • To evaluate gene alterations differences between carcinoid tumours and islet cell tumours.
  • To correlate genomic findings with treatment and clinical outcome.
  • To compare acquired data with existent available databases of whole genome or exome of neuroendocrine tumours
  • To bank remaining samples for additional exploratory analyses (e.g. further genomic testing, or DNA copy number analysis, or epigenetic evaluations).
In this prospective study the aim is to obtain fresh tumour biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumours (NETs) or well-differentiated pancreatic neuroendocrine tumours (PanNETs). Eligible population includes: NETs and PanNETs patients who have undergone or are undergoing treatment with targeted therapies and have shown prolonged clinical benefit, and NETs and PanNETs patients who have been treated with these agents and just recently progressed. RNA and DNA from fresh tumour biopsies and from mononuclear blood cells will be subjected to transcriptome sequencing and DNA sequencing analyses to evaluate possible genes of interest and related targetable pathways. Moreover, archived tumour samples will be requested from all patients to perform additional genomic testing. Remaining RNA and DNA will be banked for additional exploratory analyses (e.g. further genomic testing, or DNA copy number analysis, or epigenetic evaluations).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society